FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety
Mineo Matsumoto(Pharmaceuticals and Medical Devices Agency), Jean Sathish(Pfizer (United States)), Payal Arora(Utrecht University), Cris Kamperschroer(AVEO Oncology (United States)), Kaushik Datta(Bristol-Myers Squibb (Germany)), Suresh Kumar Swaminathan(Janssen (United States)), Rutwij Dave(Gilead Sciences (United Kingdom)), Mizuho Suzuki(Pharmaceuticals and Medical Devices Agency), Christine E. Crute(Health and Environmental Sciences Institute), Zheng Yang(Somerville Hospital), Smita Salian-Mehta(Gilead Sciences (United States)), Marie C. Fortin(Rutgers, The State University of New Jersey), Masanori Hiura(Kyowa Kirin (Japan)), J.Ryan Polli(Novartis (Switzerland)), Frank R. Brennan(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
A novel neurological mutant mouse, yotari, which exhibits reeler-like phenotype but expresses CR-50 antigen/Reelin
|Neuroscience Research|1997|141
Synaptic Plasticity in Hippocampal CA1 Neurons of Mice Lacking Type 1 Inositol-1,4,5-Trisphosphate Receptors
|Learning & Memory|2000|112
<i>In vivo</i> tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL‐2
|European Journal of Immunology|2009|35
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
Metabolic Reconfiguration Activates Stemness and Immunomodulation of PDLSCs
|International Journal of Molecular Sciences|2022|31